
The ONS Podcast
- Format:
- Podcast
- New episodes:
- Weekly
- Typical length:
- about 35 minutes
- Latest episode:
About this show
Where ONS Voices Talk Cancer
Join oncology nurses on the Oncology Nursing Society's award-winning podcast as they sit down to discuss the topics important to nursing practice and treating patients with cancer.
ISSN 2998-2308
Covers: oncology nursing, cancer care, cancer treatment, patient education, precision oncology, oncologic emergencies, hematologic cancers, nursing leadership
Show details and episodes come from the publisher's public feed at rss.libsyn.com. Last updated . Names, artwork and text belong to their publishers.
Recently on this show
Summary of recent episodes, drawn from the publisher's feed.
The ONS Podcast, from the Oncology Nursing Society, has oncology nurses discussing cancer care topics that matter to nursing practice and patients. Recent episodes cover biomarker testing, reframing care at end of life, inpatient rehabilitation during cancer treatment, Hodgkin lymphoma, and oncologic emergencies such as hypersensitivity reactions.
Cosmos
Similar by topic and creator
- Stories of Grit
Shares the topics Education and Health. - The Crappy Childhood Fairy Podcast with Anna Runkle
Shares the topics Education and Health. - The Mel Robbins Podcast
Shares the topics Education and Health.
Similar shows
- The Organic Chemistry Tutor
- The Organized Coach - Productivity, Business Systems, Time Management, ADHD, Routines, Life Coach, Entrepreneur
- The Orvis Fly-Fishing Podcast
- The Other Side NDE (Near Death Experiences)
- The Overwhelmed Brain
- The Par Train | Get Off the Struggle Bus
- The Parrot Podcast
- The Paul Parent Garden Club
Explore more
Episodes
Episode 402: Radiation Site-Specific Side Effects: Head and Neck Cancer
· 25 min
"It's important to clarify that most patients will experience and at least some side effects—and often several. So prevention really means reducing severity, complications, and long-term impact rather than avoiding side effects altogether. This process starts before radiation begins and continues throughout the treatment and includes dental evaluation, baseline swallowing assessments, and thorough patient education," ONS member Astrid Amoresano, RN, OCN®, lead oncology nurse specialist at New York Proton Center in New York, NY, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about side effects of radiation for head and neck cancer. Music Credit: "Fireflies and Stardust (http://www.incompetech.com/)" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by February 13, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to radiation side effects in people with head and neck cancer. Episode Notes - Complete this evaluation for free NCPD. - ONS Podcast™ episodes: - Cancer Symptom Management Basics series - Episode 301: Radiation Oncology: Side Effect and Care Coordination Best Practices - Episode 128: Manage Treatment-Related Radiodermatitis With ONS Guidelines™ - ONS Voice articles: - Highly Localized, Precision Radiation Therapies Require Nurses to Drive Care Coordination, Patient Education - IMRT Shows Similar Quality-of-Life Outcomes to Proton Therapy in Head and Neck Cancer - How to Handle Even the Worst Radiation Therapy Side Effects - ONS book: Manual for Radiation Oncology Nursing Practice and Education (fifth edition) - ONS courses: - ONS/ONCC® Radiation Therapy Certificate™ - ONS Oncology Symptom Management - Clinical Journal of Oncology Nursing articles: - The Role of Advanced Practice Providers in Radiation Oncology in 2025 (https://doi.org/10.1188/25.CJON.279-284) - Systematic Review of Malnutrition Risk Factors to Identify Nutritionally At-Risk Patients With Head and Neck Cancer (https://doi.org/10.1188/24.CJON.197-208) - Effects of a Nurse-Initiated Telephone Care Path for Pain Management in Patients With Head and Neck Cancer Receiving Radiation Therapy (https://doi.org/10.1188/23.CJON.143-146) - Radiation-Induced Skin Dermatitis: Treatment With CamWell® Herb to Soothe® Cream in Patients With Head and Neck Cancer Receiving Radiation Therapy (https://doi.org/10.1188/21.CJON.E44-E49) - ONS Radiation Learning Library - ONS Symptom Intervention Resources (https://www.ons.org/clinical-tools/pep) - ONCC: Radiation Oncology Certified Nurse (ROCN™) - American Cancer Society - CA: A Cancer Journal for Clinicians article: American Cancer Society Head and Neck Cancer Survivorship Care Guideline - Cancer Survivors Network: Head and neck cancer - Head and neck cancer resources - Radiation therapy resources - American Society of Radiation Oncology (https://www.astro.org/) - National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE) - National Comprehensive Cancer Network (https://www.nccn.org) To discuss the information in this episode with other oncology nurses, visit the ONS Communities (http://communities.ons.org/). To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Many tumors in the region are very radiosensitive, and radiation can be used either…
Not rated yetEpisode 401: Multiple Myeloma Treatment Considerations for Oncology Nurses
· 37 min
"You also want to deal with patient preferences. We do want to get their disease under control. We want to make them live a long, good quality of life. But do they want to come to the clinic once a week? Is it a far distance? Is geography a problem? Do they prefer not taking oral chemotherapies at home? We have to think about what the patient's preferences are to some degree and kind of incorporate that in our decision-making plan for treatments for relapsed and refractory myeloma," Ann McNeill, RN, MSN, APN, nurse practitioner at the John Theurer Cancer Center at Jersey Shore University Medical Center in Neptune, NJ, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about multiple myeloma treatment considerations. Music Credit: "Fireflies and Stardust (http://www.incompetech.com/)" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by February 6, 2027. Ann McNeill has disclosed a speakers bureau relationship with Pfizer. This financial relationship has been mitigated. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the treatment of multiple myeloma. Episode Notes - Complete this evaluation for free NCPD. - ONS Podcast™ episodes: - Episode 398: An Overview of Multiple Myeloma for Oncology Nurses - Episode 395: Pharmacology 101: Monoclonal Antibodies - Episode 372: Pharmacology 101: Proteasome Inhibitors - ONS Voice articles: - Effective Care Transitions Are Essential for New Multiple Myeloma Treatments - New Multiple Myeloma Treatments Present New Challenges in Side Effect Management - Reduce Racial Barriers and Care Inequities for Black and African American Patients With Multiple Myeloma - ONS Voice FDA approval alerts - ONS Voice oncology drug reference sheets: - Belantamab mafodotin-blmf - Daratumumab - Motixafortide - Selinexor - Clinical Journal of Oncology Nursing articles: - Journey of a Patient With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation - Optimizing Transitions of Care in Multiple Myeloma Immunotherapy: Nurse Roles - Oncology Nursing Forum article: Facilitators of Multiple Myeloma Treatment: A Qualitative Study - ONS books: - Hematopoietic Stem Cell Transplantation: A Manual for Nursing Practice (third edition) - Multiple Myeloma: A Textbook for Nurses (third edition) - ONS course: ONS Hematopoietic Stem Cell Transplantation™ - ONS Huddle Cards: - Financial Toxicity - Hematopoietic Stem Cell Transplantation (HSCT) - Monoclonal Antibodies - ONS Hematology, Cellular Therapy, and Stem Cell Transplantation Learning Library - American Society of Clinical Oncology (ASCO)–Ontario Health: Treatment of Multiple Myeloma Living Guideline - International Myeloma Foundation: - Clinical Trials Fact Sheets - Clinical Trial Support (https://www.myeloma.org/sparkcures/) - Resource Library (https://www.myeloma.org/publications-videos) - Multiple Myeloma Research Foundation resource: Treatments for Multiple Myeloma To discuss the information in this episode with other oncology nurses, visit the ONS Communities (http://communities.ons.org/). To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Typically for our first-line therapies, we use certain classes of drugs and some of them are proteasome inhibitors like bortezomib and carfilzomib. We also have IMiDs or immunomodulatory agents like thalidomide, lenalidomide, and pomalidomide. We have monoclonal antibodies, anti-CD38 monoclonal…
Not rated yetEpisode 400: Pharmacology 101: Radioimmunoconjugates
· 14 min
"Radioimmunoconjugates work through a dual mechanism that combines immunologic targeting with localized radiation delivery. The monoclonal antibody components bind to specific tumor-associated antigens such as CD20, expressed on malignant B cells. Once found, the attached radioisotope delivers beta radiation directly to the tumor, causing DNA damage and cell death," Sabrina Enoch, MSN, RN, OCN®, CNMT, NMTCB (CT), theranostics clinical specialist at Highlands Oncology in Rogers, AR, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about radioimmunoconjugates. Music Credit: "Fireflies and Stardust (http://www.incompetech.com/)" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.25 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by January 30, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge in the history of, the mechanism of action of, and the use of radioimmunoconjugates in the treatment of cancer. Episode Notes - Complete this evaluation for free NCPD. - ONS Podcast™ episodes: - Pharmacology 101 series - Episode 377: Creating and Implementing Radiopharmaceutical Policies and Procedures - Episode 301: Radiation Oncology: Side Effect and Care Coordination Best Practices - Episode 298: Radiation Oncology: Nursing's Essential Roles - ONS Voice articles: - Interprofessional Collaboration Reduces Time to Neutropenia Antibiotic Administration - Radiopharmaceuticals and Theranostics Offer New Options for Oncology Nurses to Transform Cancer Care - Radiopharmaceuticals Pack a One-Two Punch Against Cancer - Safety Is Key in Use of Radiopharmaceuticals - Telehealth Has Value During Radiotherapy, Patients Say - ONS Voice oncology drug reference sheets: - Lutetium Lu 177 dotatate - Lutetium Lu 177 vipivotide tetraxetan - Radium 223 dichloride - Sodium iodide-131 - Strontium chloride Sr-89 - ONS books: - Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) - Manual for Radiation Oncology Nursing Practice and Education (fifth edition) - ONS courses: - ONS/ONCC® Chemotherapy Immunotherapy Certificate™ - ONS/ONCC® Radiation Therapy Certificate™ - Clinical Journal of Oncology Nursing articles: - Radiopharmaceutical Safety: Making It Easy - Targeted Radionuclide Therapy: A Theranostic Approach to Cancer Therapy - ONS Huddle Cards: - Radiobiology - Radiopharmaceuticals - ONS Learning Libraries: - Immuno-Oncology - Radiation - ONS Symptom Interventions for Prevention of Bleeding - Drugs@FDA package inserts To discuss the information in this episode with other oncology nurses, visit the ONS Communities (http://communities.ons.org/). To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Radioimmunoconjugates are a specialized subset of radiopharmaceuticals designed to combine the specificity of monoclonal antibodies with the cytotoxic power of radiation. ... Early development focused on B-cell malignancies, particularly non-Hodgkin lymphoma." TS 1:51 "An important concept for nurses to understand is the crossfire effect, where radiation can affect nearby tumor cells, even though not every cell expressed has the target antigen. This helps explain why these agents can be effective even in heterogeneous tumors." TS 3:40 "At present, 90 Y-ibritumomab tiuxetan is the only radioimmunoconjugate approved by the U.S.…
Not rated yetEpisode 399: National Hazardous Drug Exposure Registry
· 39 min
"The United States does not have a national cancer registry. We have a bunch of state registries. Some of those registries do collaborate and share information, but the issue is the registries that do exist typically do not report cancer by occupation. So, we cannot get our arms around the potential work-relatedness of the health outcome given the current way the state registries collect information. What we're trying to set up, is a way to make what is currently an invisible risk, visible," ONS member Melissa McDiarmid, MD, MPH, DABT, professor of medicine and epidemiology and public health director of the division of occupational and environmental medicine at the University of Maryland School of Medicine in Baltimore, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the University of Maryland School of Medicine Hazardous Drug Safety Center Exposure Registry. Music Credit: "Fireflies and Stardust (http://www.incompetech.com/)" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by January 23, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge in the incidence of hazardous drug exposure and the tracking and reporting of healthcare worker exposures. Episode Notes - Complete this evaluation for free NCPD. - University of Maryland School of Medicine Hazardous Drug Safety Center Exposure Registry information sheet - ONS Podcast™ episodes: - Episode 330: Stay Up to Date on Safe Handling of Hazardous Drugs - Episode 308: Hazardous Drugs and Hazardous Waste: Personal, Patient, and Environmental Safety - Episode 209: Updates in Chemo PPE and Safe Handling - ONS Voice articles: - Hazardous Drug Surface Contamination Prevails, Despite More Diligent PPE - National Hazardous Drug Exposure Registry Safeguards Oncology Professionals - NIOSH Releases Its 2024 List of Hazardous Drugs - Safe Handling—We've Come a Long Way, Baby! - Strategies to Promote Safe Medication Administration Practices - Surfaces in Patient Bathrooms Often Contaminated With HDs, Despite Use of Plastic-Backed Pads - ONS books: - Safe Handling of Hazardous Drugs (fourth edition) - Safe Handling of Hazardous Drugs Quick Guide™ - ONS course: Safe Handling Basics - Clinical Journal of Oncology Nursing articles: - Hazardous Drug Exposure: Case Report Analysis From a Prospective, Multisite Study of Oncology Nurses' Exposure in Ambulatory Settings - Personal Protective Equipment Use and Surface Contamination With Antineoplastic Drugs: The Impact of the COVID-19 Pandemic - Sequential Wipe Testing for Hazardous Drugs: A Quality Improvement Project - The Use of Plastic-Backed Pads to Reduce Hazardous Drug Contamination - Oncology Nursing Forum articles: - Ensuring Healthcare Worker Safety When Handling Hazardous Drugs - Factors Influencing Nurses' Use of Hazardous Drug Safe Handling Precautions - Other ONS resources: - ONS Safe Handling of Hazardous Drugs Quick Guide - Introduction to Safe Handling Huddle Card - Safe Handling of Hazardous Drugs Learning Library - Hematology/Oncology Pharmacy Association (HOPA) course: Safe Handling of Hazardous Drugs - National Institute for Occupational Safety and Health (NIOSH) List of Hazardous Drugs in Healthcare Settings, 2024 To discuss the information in this episode with other oncology nurses, visit the ONS Communities (http://communities.ons.org/). To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To…
Not rated yetEpisode 398: An Overview of Multiple Myeloma for Oncology Nurses
· 43 min
"[Multiple myeloma] is very treatable, very manageable, but right now it is still considered an incurable disease. So, patients are on this journey with myeloma for the long term. It's very important for us to realize that during their journey, we will see them repeatedly. They are going to be part of our work family. They will be with us for a while. I think it's our job to be their advocate. To be really focused on not just the disease, but periodically assessing that financial burden and psychosocial aspect," Ann McNeill, RN, MSN, APN, nurse practitioner at the John Theurer Cancer Center at Jersey Shore University Medical Center in Neptune, NJ, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about multiple myeloma. Music Credit: "Fireflies and Stardust (http://www.incompetech.com/)" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by January 16, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the pathophysiology and diagnosis of multiple myeloma. Episode Notes - Complete this evaluation for free NCPD. - ONS Podcast™ episodes: - Episode 332: Best Nursing Practices for Pain Management in Patients With Cancer - Episode 256: Cancer Symptom Management Basics: Hematologic Complications - Episode 192: Oncologic Emergencies 101: Hypercalcemia of Malignancy - ONS Voice articles: - AI Multiple Myeloma Model Predicts Individual Risk, Outcomes, and Genomic Implications - Cancer Mortality Declines Among Black Patients but Remains Disproportionately High - Financial Navigation During Hematologic Cancer Saves Patients and Caregivers $2,500 - Multiple Myeloma: Detecting Genetic Changes Through Bone Marrow Biopsy and the Influence on Care - Multiple Myeloma Prevention, Screening, Treatment, and Survivorship Recommendations - Nurse-Led Bone Marrow Biopsy Clinics Truncate Time for Testing, Treatment - Diagnose and Treat Hypercalcemia of Malignancy - ONS books: - BMTCN® Certification Review Manual (second edition) - Multiple Myeloma: A Textbook for Nurses (third edition) - Clinical Journal of Oncology Nursing articles: - African American Patients With Multiple Myeloma: Optimizing Care to Decrease Racial Disparities - Music Intervention: Nonpharmacologic Method to Reduce Pain and Anxiety in Adult Patients Undergoing Bone Marrow Procedures - Other ONS resources: - Financial Toxicity Huddle Card - Hypercalcemia of Malignancy Huddle Card - Hematology, Cellular Therapy, and Stem Cell Transplantation Learning Library - American Cancer Society article: What Is Multiple Myeloma? - Blood Cancer United educational resources page - International Myeloma Foundation homepage (https://www.myeloma.org/) - Myeloma University homepage (https://university.myeloma.org/) - Multiple Myeloma Research Foundation (MMRF) article: Understanding Multiple Myeloma To discuss the information in this episode with other oncology nurses, visit the ONS Communities (http://communities.ons.org/). To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Epidemiologically, myeloma is a cancer of older adults. The median age is about 69. It is more common in men than women. It's a ratio of about three men to two women that are diagnosed. It is much more common in people of African American descent with increasing global incidence linked…
Not rated yetEpisode 397: Cancer Symptom Management Basics: Ototoxicity
· 37 min
"Referring patients to audiology early on has shown dramatic reduction in hearing loss or complications because the audiologist can really see where were they at before they started chemotherapy, where were they at during, if they get an audiogram during their treatment. And then after treatment, it's really important for them to see an audiologist because this is really a survivorship journey for them. And as nurses, the 'so what': We are the first line of defense," ONS member Jennessa Rooker, PhD, RN, OCN®, director of nursing excellence at the Tampa General Hospital Cancer Institute in Florida, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about ototoxicity in cancer care. Music Credit: "Fireflies and Stardust (http://www.incompetech.com/)" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by January 9, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the management of ototoxicity after chemotherapy treatment. Episode Notes - Complete this evaluation for free NCPD. - ONS Podcast™ Cancer Symptom Management Basics series - ONS Voice articles: - Oncology Drug Reference Sheet: Cisplatin - Oncology Drug Reference Sheet: Carboplatin - Oncology Drug Reference Sheet: Oxaliplatin - FDA Approves Sodium Thiosulfate for Cisplatin-Associated Ototoxicity in Pediatric Patients - ONS book: Clinical Manual for the Oncology Advanced Practice Nurse (fourth edition) - American Cancer Society resources: - 4 Causes of Hearing Problems for Cancer Survivors - Cancer Survivors Network (https://csn.cancer.org/) - American Speech-Language-Hearing Association (ASHA) (https://www.asha.org/) - Hearing Loss: An Under-Recognized Side Effect of Cancer Treatment - Embedded Ear Care: Audiology on the Cancer Treatment Team - American Society of Clinical Oncology (ASCO) Annual Meeting abstract: Innovative Infusion Center Assessments of Chemotherapy-Induced Neurotoxicities: A Pilot Study Supporting Early and Routine Screenings as Part of Survivorship Programs - Children's Oncology Group supportive care endorsed guideline: Prevention of Cisplatin-Induced Ototoxicity in Children and Adolescents With Cancer: A Clinical Practice Guideline - Ear and Hearing article: Roadmap to a Global Template for Implementation of Ototoxicity Management for Cancer Treatment - International Ototoxicity Management Group (IOMG) - IOMG Wikiversity page - Shoebox hearing assessments (https://www.shoebox.md/) - World Health Organization initiative: Make Listening Safe To discuss the information in this episode with other oncology nurses, visit the ONS Communities (http://communities.ons.org/). To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "At different pitches, the eardrums move faster or slower, signaling the inner ear, or the cochlea—the thing that looks like a snail in the pictures. The cochlea has fluid and hair cells inside of it that receive movements from the eardrum. The hair cells change the movement into electrical signals that actually go to the auditory nerves or the cranial nerve VIII." TS 2:15 "Ototoxicity is an umbrella term for some sort of exposure to a toxin that causes damage to the inner ear. These toxins can be in the environment, such as loud or different noises, or they can be from medications,…
Not rated yetEpisode 396: Nursing Considerations From the ONS/ASCO Extravasation Guideline
· 28 min
"We proposed a concept to the American Society of Clinical Oncology (ASCO), recognizing that extravasation management requires significant interdisciplinary collaboration and rapid action. There can occasionally be uncertainty or lack of clear guidance when an extravasation event occurs, and our objective was to look at this evidence with the expert panel to create a resource to support oncology teams overall. We hope that the guideline can help mitigate harm and improve patient outcomes," Caroline Clark, MSN, APRN, AGCNS-BC, OCN®, EBP-C, director of guidelines and quality at ONS, told Chelsea Backler, MSN, APRN, AGCNS-BC, AOCNS®, VA-BC, oncology clinical specialist at ONS, during a conversation about the ONS/ASCO Guideline on the Management of Antineoplastic Extravasation. Music Credit: "Fireflies and Stardust (http://www.incompetech.com/)" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by January 2, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the management of antineoplastic extravasation. Episode Notes - Complete this evaluation for free NCPD. - ONS/ASCO Guideline on the Management of Antineoplastic Extravasation - ONS Podcast™ episodes: - Episode 391: Pharmacology 101: Antibody–Drug Conjugates - Episode 335: Ultrasound-Guided IV Placement in the Oncology Setting - Episode 145: Administer Taxane Chemotherapies With Confidence - Episode 127: Reduce and Manage Extravasations When Administering Cancer Treatments - ONS Voice articles: - Access Devices and Central Lines: New Evidence and Innovations Are Changing Practice, but Individual Patient Needs Always Come First - New Extravasation Guidelines Provide Recommendations for Protecting Patients and Standardizing Care - Standardizing Venous Access Assessment and Validating Safe Chemo Administration Drastically Lowers Rates of Adverse Venous Events - This Organization's Program Trains Non-Oncology Nurses to Deliver Antineoplastic Agents Safely - ONS books: - Access Device Guidelines: Recommendations for Nursing Practice and Education (fourth edition) - Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) - Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) - ONS courses: - Complications of Vascular Access Devices (VAD) and IV Therapy - ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ - ONS Oncology Treatment Modalities - Clinical Journal of Oncology Nursing articles: - Chemotherapy Extravasation: Incidence of and Factors Associated With Events in a Community Cancer Center - Standardized Venous Access Assessment and Safe Chemotherapy Administration to Reduce Adverse Venous Events - Oncology Nursing Forum article: Management of Extravasation of Antineoplastic Agents in Patients Undergoing Treatment for Cancer: A Systematic Review - ONS huddle cards: - Antineoplastic Administration - Chemotherapy - Immunotherapy - Implanted Venous Port - ONS position statements: - Administration (Infusion and Injection) of Antineoplastic Therapies in the Home - Education of the Nurse Who Administers and Cares for the Individual Receiving Antineoplastic Therapies - ONS Guidelines™ for Extravasation Management - ONS Oncologic Emergencies Learning Library - ONS/ASCO Algorithm on the Management of Antineoplastic Extravasation of Vesicant or Irritant With Vesicant Properties in Adults - American Society of Clinical Oncology (ASCO) Podcast: Management of Antineoplastic Extravasation: ONS-ASCO…
Not rated yetEpisode 395: Pharmacology 101: Monoclonal Antibodies
· 45 min
"They [monoclonal antibodies] are able to cause tumor cell death by binding to and blocking to necessary growth factor signaling pathways for tumor cell survival. That's going to be dependent on the target of the antibody, but I'll give an example of epidermal growth factor, or EGFR. This is overexpressed in several different kinds of cancers where activation of this growth factor increases the amount of proliferation and migration of cancer cells. So, if we bind to it and block to it, then that would help halt these pathways and stop cancer cell growth," Carissa Ganihong, PharmD, BCOP, oncology and bone marrow transplantation clinical pharmacist at Hackensack University Medical Center in New Jersey, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about monoclonal antibodies. Music Credit: "Fireflies and Stardust (http://www.incompetech.com/)" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.75 contact hours of nursing continuing professional development (NCPD) (including 45 minutes of pharmacotherapeutic content) by listening to the full recording and completing an evaluation at courses.ons.org by December 26, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge in the history of, the mechanism of action of, and the use of monoclonal antibodies in the treatment of cancer. Episode Notes - Complete this evaluation for free NCPD. - ONS Podcast™ episodes: - Pharmacology 101 series - Episode 391: Pharmacology 101: Antibody–Drug Conjugates - Episode 383: Pharmacology 101: Bispecific Antibodies - Episode 375: Pharmacology 101: VEGF Inhibitors - Episode 338: High-Volume Subcutaneous Injections: The Oncology Nurse's Role - Episode 283: Desensitization Strategies to Reintroduce Treatment After an Infusion-Related Reaction - Episode 275: Bispecific Monoclonal Antibodies in Hematologic Cancers and Solid Tumors - ONS Voice articles: - An Oncology Nursing Overview of Biosimilars - Make Subcutaneous Administration More Comfortable for Your Patients - Oncology Nurses' Role in Translating Biomarker Testing Results - Reduce Chair Time by as Much as 16 Minutes by Priming IVs With Drug - Shorter Administration Times Still Require High-Acuity Care - The Names of Targeted Therapies Give Clues to How They Work - ONS Voice drug reference sheets: - Datopotamab deruxtecan-dlnk - Enfortumab vedotin - Margetuximab-cmkb - Mirvetuximab soravtansine-gynx - Nivolumab and hyaluronidase-nvhy - Nivolumab and relatlimab-rmbw - Pembrolizumab and berahyaluronidase alfa-pmph - Retifanlimab-dlwr - ONS book: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) - ONS course: ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ - Clinical Journal of Oncology Nursing articles: - Bolusing IV Administration Sets With Monoclonal Antibodies Reduces Cost and Chair Time: A Randomized Controlled Trial - Management of Immunotherapy Infusion Reactions - Nurse-Led Grading of Antineoplastic Infusion-Related Reactions: A Call to Action - Safety and Adverse Event Management of VEGFR-TKIs in Patients With Metastatic Renal Cell Carcinoma - Oncology Nursing Forum articles: - Administration of Subcutaneous Monoclonal Antibodies in Patients With Cancer - Depressive Symptoms and Quality of Life Associated With the Use of Monoclonal Antibodies in Breast Cancer Treatment - ONS huddle cards: - Bispecifics - Checkpoint Inhibitors - Monoclonal Antibodies - Other ONS resources: - Biomarker Database - Bispecific Antibodies video - Patient Education Sheets (https://patienteducationsheets.com/) - Antibodies article: A…
Not rated yetEpisode 394: Prostate Cancer Survivorship Considerations for Nurses
· 20 min
"The thought of recurrence is also a psychosocial issue for our patients. They're being monitored very closely for five years, so there's always that thought in the back of their head, 'What if the cancer comes back? What are the next steps? What am I going to do next?' It's really important that we have conversations with patients and their families about where they're at, what we're looking for, and reassure them that we'll be with them during this journey and help them through whatever next steps happen," ONS member Clara Beaver, DNP, RN, AOCNS®, ACNS-BC, manager of clinical education and clinical nurse specialist at Karmanos Cancer Institute in Detroit, MI, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about prostate cancer survivorship considerations for nurses. Music Credit: "Fireflies and Stardust (http://www.incompetech.com/)" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by December 19, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to survivorship nursing considerations for people with prostate cancer. Episode Notes - Complete this evaluation for free NCPD. - ONS Podcast™ episodes: - Episode 390: Prostate Cancer Treatment Considerations for Nurses - Episode 387: Prostate Cancer Screening, Early Detection, and Disparities - Episode 201: Which Survivorship Care Model Is Right for Your Patient? - Episode 194: Sex Is a Component of Patient-Centered Care - ONS Voice articles: - APRNs Collaborate With PCPs on Shared Survivorship Care Models - Exercise Before ADT Treatment Reduces Rate of Side Effects - Frank Conversations Enhance Sexual and Reproductive Health Support During Cancer - Here Are the Current Nutrition and Physical Activity Recommendations for Cancer Survivors - Nursing Considerations for Prostate Cancer Survivorship Care - Regular Physical Activity and Healthy Diet Lower Risk of All-Cause and Cardiac Mortality in Prostate Cancer Survivors - Sexual Considerations for Patients With Cancer - Sleep Disturbance Is Part of a Behavioral Symptom Cluster in Prostate Cancer Survivors - ONS course: Essentials in Survivorship Care for the Advanced Practice Provider - Clinical Journal of Oncology Nursing articles: - A Patient-Specific, Goal-Oriented Exercise Algorithm for Men Receiving Androgen Deprivation Therapy - Incorporating Nurse Navigation to Improve Cancer Survivorship Care Plan Delivery - Prostate Cancer: Survivorship Care Case Study, Care Plan, and Commentaries - The Role of the Advanced Practice Provider in Bone Health Management for the Prostate Cancer Population - Oncology Nursing Forum articles: - A Qualitative Exploration of Prostate Cancer Survivors Experiencing Psychological Distress: Loss of Self, Function, Connection, and Control - Identification of Symptom Profiles in Prostate Cancer Survivors - Sleep Hygiene Education, ReadiWatch™ Actigraphy, and Telehealth Cognitive Behavioral Training for Insomnia for People With Prostate Cancer - Understanding Men's Experiences With Prostate Cancer Stigma: A Qualitative Study - Other ONS resources: - Late Effects of Cancer Treatment Huddle Card - Survivorship Care Plan Huddle Card - Survivorship Learning Library - American Cancer Society (ACS): Living as a Prostate Cancer Survivor - ACS prostate cancer survivorship studies To discuss the information in this episode with other oncology nurses, visit the ONS Communities (http://communities.ons.org/). To find resources for creating an ONS…
Not rated yetEpisode 393: Antibody–Drug Conjugates in Metastatic Breast Cancer
· 20 min
"I'll go back to the backpack analogy. When your kids come home with a backpack, all of a sudden their homework is not on the desk where it's supposed to be. It's in the kitchen; it kind of spreads all over the place, but it's still in the house. When we give antibody–drug conjugates (ADCs), the chemotherapy does go in, but then it can kind of permeate out of the cell membrane and something right next to it—another cancer cell that might not look exactly like the cancer cell that the chemotherapy was delivered into—is affected and the chemotherapy goes over to that cancer cell and kills it," ONS member Marisha Pasteris, OCN®, office practice nurse in the breast medicine service at Memorial Sloan Kettering Cancer Center in New York, NY, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about ADCs in metastatic breast cancer. Music Credit: "Fireflies and Stardust (http://www.incompetech.com/)" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 This podcast is sponsored by Gilead and is not eligible for NCPD contact hours. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications. Episode Notes - This episode is not eligible for NCPD. - ONS Podcast™ episodes: - Episode 391: Pharmacology 101: Antibody–Drug Conjugates - Episode 378: Considerations for Adolescent and Young Adult Patients With Metastatic Breast Cancer - Episode 368: Best Practices for Challenging Patient Conversations in Metastatic Breast Cancer - Episode 350: Breast Cancer Treatment Considerations for Nurses - Episode 303: Cancer Symptom Management Basics: Ocular Toxicities - ONS Voice articles: - An Oncology Nurse's Guide to Cancer-Related Ocular Toxicities - Black Patients With Metastatic Breast Cancer Are Less Informed About Their Clinical Trial Options - Communication Case Study: Talking to Patients About Progressive Metastatic Breast Cancer - What Is HER2-Low Breast Cancer? - ONS Voice drug reference sheets: - Belantamab mafodotin-blmf - Datopotamab deruxtecan-dlnk - Enfortumab vedotin-ejfv - Fam-trastuzumab deruxtecan-nxki - ONS books: - Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) - Guide to Breast Care for Oncology Nurses - Guide to Cancer Immunotherapy (second edition) - ONS courses: - ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ - ONS/ONCC® Chemotherapy Immunotherapy Certificate™ - Clinical Journal of Oncology Nursing article: - Antibody–Drug Conjugates and Ocular Toxicity: Nursing, Patient, and Organizational Implications for Care - The Association Between Hormone Receptor Status and End-of-Life Care Among Patients With Metastatic Breast Cancer - Oncology Nursing Forum article: Impact of Race and Area Deprivation on Triple-Negative Metastatic Breast Cancer Outcomes - ONS huddle cards: - Altered Body Image Huddle Card - Chemotherapy Huddle Card - Targeted Therapy Huddle Card - Foundations of Antibody–Drug Conjugate Use in Metastatic Breast Cancer: A Case Study - ONS Biomarker Database (https://www.ons.org/clinical-tools/biomarkers) (refine by breast cancer) - ONS Breast Cancer Learning Library - American Society of Clinical Oncology (https://www.asco.org/) (ASCO) homepage - Drugs@FDA package inserts - National Comprehensive Cancer Network homepage (https://www.nccn.org/) - Susan G. Komen metastatic breast cancer page (https://www.komen.org/breast-cancer/metastatic/) To discuss the information in this episode with other oncology nurses, visit the ONS Communities (http://communities.ons.org/). To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "What an ADC is doing is taking the antibody and linking it to a…
Not rated yet